These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 498534)

  • 21. Carrier detection in X-linked Becker muscular dystrophy by muscle provocation test (MPT).
    Herrmann FH; Spiegler AW
    J Neurol Sci; 1983 Dec; 62(1-3):141-6. PubMed ID: 6668470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of creatine kinase in sera from healthy women, carriers of Duchenne muscular dystrophy and cord blood, determined by the "European" recommended method with NAC-EDTA activation.
    Moss DW; Whitaker KB; Parmar C; Heckmatt J; Wikowski J; Sewry C; Dubowitz V
    Clin Chim Acta; 1981 Oct; 116(2):209-16. PubMed ID: 6794955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of serum creatine phosphokinase in genetic counseling for Duchenne muscular dystrophy. I. Analysis of results from 29 studies.
    Gale AN; Murphy EA
    J Chronic Dis; 1978 Feb; 31(2):101-9. PubMed ID: 659567
    [No Abstract]   [Full Text] [Related]  

  • 24. Creatine phosphokinase levels in the newborn and their use in screening for Duchenne muscular dystrophy.
    Drummond LM
    Arch Dis Child; 1979 May; 54(5):362-6. PubMed ID: 475411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carrier detection in Duchenne muscular dystrophy. Evidence from a study of obligatory carriers and mothers of isolated cases.
    Sibert JR; Harper PS; Thompson RJ; Newcombe RG
    Arch Dis Child; 1979 Jul; 54(7):534-7. PubMed ID: 485196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of carrier status in Duchenne dystrophy by creatine kinase measurement.
    Gruemer HD; Miller WG; Chinchilli VM; Leshner RT; Blasco PA; Hassler CR; Nance WE
    Am J Clin Pathol; 1985 Nov; 84(5):655-8. PubMed ID: 4061390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Change of serum creatine phosphokinase activity after exercise in Duchenne type of progressive muscular dystrophy.
    Nakane K
    Nagoya Med J; 1972 Feb; 17(3):203-16. PubMed ID: 5050757
    [No Abstract]   [Full Text] [Related]  

  • 28. Myoglobinaemia in Duchenne muscular dystrophy patients and carriers: A new adjunct to carrier detection.
    Adornato BT; Kagen LJ; Engel WK
    Lancet; 1978 Sep; 2(8088):499-501. PubMed ID: 79868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors affecting serum creatine phosphokinase levels in normal adult females.
    Paterson Y; Lawrence EF
    Clin Chim Acta; 1972 Nov; 42(1):131-9. PubMed ID: 4654849
    [No Abstract]   [Full Text] [Related]  

  • 30. Letter: Follow-up study of serum-creatine-kinase in carriers of Duchenne muscular dystrophy.
    Moser H; Vogt J
    Lancet; 1974 Sep; 2(7881):661-2. PubMed ID: 4137773
    [No Abstract]   [Full Text] [Related]  

  • 31. Racial effect on serum creatine-kinase: implications for estimation of heterozygosity risks for females at-risk for Duchenne dystrophy.
    Passos-Bueno MR; Rabbi-Bortolini E; Azevêdo E; Zatz M
    Clin Chim Acta; 1989 Feb; 179(2):163-8. PubMed ID: 2920447
    [No Abstract]   [Full Text] [Related]  

  • 32. Duchenne muscular dystrophy. Genetic aspects, carrier detection and antenatal diagnosis.
    Emery AE
    Br Med Bull; 1980 May; 36(2):117-22. PubMed ID: 7020836
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of normal daughters' and sisters' creatine kinase levels in estimating heterozygosity in Duchenne muscular dystrophy.
    Emery AE; Holloway S
    Hum Hered; 1977; 27(2):118-26. PubMed ID: 863458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of concomitant serum pyruvate-kinase (PK) and creatine-phosphokinase (CPK) for carrier detection in Duchenne's muscular dystrophy through discriminant analysis.
    Zatz M; Otto PA
    J Neurol Sci; 1980 Sep; 47(3):411-7. PubMed ID: 7420115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum creatine phosphokinase and pyruvate kinase in neuromuscular disorders and Duchenne dystrophy carriers.
    Seay AR; Ziter FA; Wu LH; Wu JT
    Neurology; 1978 Oct; 28(10):1047-50. PubMed ID: 570660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of carriers of X-linked gene for Duchenne muscular dystrophy by levels of creatine kinase and pyruvate kinase.
    Falcão-Conceição DN; Gonçalves-Pimentel MM; Baptista ML; Ubatuba S
    J Neurol Sci; 1983 Dec; 62(1-3):171-80. PubMed ID: 6668472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carrier detection in Becker muscular dystrophy using creatine kinase estimation and DNA analysis.
    Kingston HM; Sarfarazi M; Newcombe RG; Willis N; Harper PS
    Clin Genet; 1985 Apr; 27(4):383-91. PubMed ID: 3995787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variation of serum creatine kinase levels with age in normal females: implications for genetic counselling in Duchenne muscular dystrophy.
    Lane RJ; Roses AD
    Clin Chim Acta; 1981 Jun; 113(1):75-86. PubMed ID: 7237844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Muscle provocation test. A sensitive method for discrimination between carriers and noncarriers of Duchenne muscular dystrophy.
    Herrmann FH; Spiegler A; Wiedemann G
    Hum Genet; 1982; 61(2):102-4. PubMed ID: 7129438
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of age on the detection rate in Duchenne muscular dystrophy.
    Zatz M; Otto PA
    J Neurol Sci; 1980 Sep; 47(3):407-10. PubMed ID: 7420114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.